Abbott, the global healthcare company, has launched XIENCE Skypoint in India. This is the company said is the most advanced generation stent within the globally trusted XIENCE family of everolimus (drug)-eluting coronary stents. The stent is designed to be more flexible, easier to guide through the heart’s arteries, including large vessels, and better suited for treating complex heart blockages.
Tushar Sharma, general manager, Abbott’s vascular business in India and South Asia said, “The launch of XIENCE Skypoint in India represents an advancement for doctors treating cardiovascular disease, which remains a leading cause of mortality in India. Many patients today develop severe blockages earlier in life due to rising hypertension, diabetes, cholesterol, and lifestyle risks. This makes it essential to support doctors with stents that can safely reach difficult areas and treat a wide range of blockages. XIENCE Skypoint brings improvements with precision and strengthens our commitment to providing advanced heart treatments across the country.”
Abbott has introduced newer generations of XIENCE, with the goal of providing physicians with access to the latest DES technology. With this launch, XIENCE Skypoint brings the broadest size matrix ever offered by the XIENCE family, supporting the treatment of long lesions while helping reduce the number of stents required per procedure. The platform also introduces 4.5 mm and 5.0 mm diameters, making it the only DES indicated for vessels up to 5.25 mm. This is especially important because real-world patients at times have bigger or more varied artery sizes that need the right fit.
With XIENCE Skypoint, doctors have the option of using a 48 mm single-stent, allowing them to treat longer lesions with one stent instead of multiple ones. This can reduce procedure time, radiation exposure, and contrast dye usage for patients.
XIENCE Skypoint is designed to move more easily through the heart’s arteries. It uses a slim and smooth delivery system that helps doctors guide the stent through tight or winding passages with better control. These improvements make it easier to reach tough blockages, supporting reliable performance even in complicated cases.
The company said that the stent is built on the established XIENCE legacy, one of the world’s most studied DES platforms. It is supported by years of clinical evidence, with over 120 clinical trials3 and 10 years of clinical data. Globally, there have been 20 million+ implants using XIENCE stents. The stent is also backed by Abbott’s proprietary fluoropolymer coating, and a proven cobalt-chromium structure, continuing a long-standing record of safety and durable outcomes. |